OA21.03 A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation

Savolitinib is a potent and highly selective oral MET tyrosine-kinase inhibitor, and it has indicated a preliminary efficacy in patients with MET exon 14 (METex14)-mutated NSCLCs. The phase 3b study was conducted to evaluate the efficacy, safety and tolerability of savolitinib for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) harboring METex14 mutation.